Liu X, et al. - In this retrospective study, researchers tested gemcitabine, cisplatin, prednisone, and thalidomide (GDPT) regimen for relapsed/refractory peripheral T-cell lymphoma (PTCL), focusing on the efficacy and safety of this regimen. Participants were 29 patients in whom this regimen was used as salvage protocol for PTCL that failed in first-line therapy. Following the administration of 106 cycles of GDPT regimen, they found a disease control rate and overall response rate of 82.8% and 69.0%, respectively. Complete remission and partial remission were 34.5% and 34.5%, respectively. The observed median progression-free survival (PFS) and median OS was 10.0 months and 28.0 months, respectively. The 1-year PFS rate was 43.6% and 1-year OS rate was 64.6%. Moderate and well-tolerated hematologic and non-hematologic toxicities were experienced. No treatment-associated death was reported. Experts concluded that thalidomide in combination with gemcitabine, cisplatin, prednisone regimen affords a novel promising strategy to manage patients with relapse and refractory PTCL.